Please assess the completion status of the following clinical trial:

Trial Title: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inoperable estrogen receptor positive and HER2 negative breast cancer.~* Postmenopausal status.~* Tumor tissue (archived acceptable) available for biomarker studies. For Phase 2 Part 2 - CCND1 amplification and/or loss of p16 as determined by the central laboratory.~* Acceptable bone marrow, liver and kidney function.~Exclusion Criteria:~* Prior or concomitant treatment for advanced breast cancer.~* Other major cancer in the past 3 years.~* Important cardiovascular events in the past 6 months.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): letrozole + PD 0332991
- Arm B (Type: ACTIVE_COMPARATOR): letrozole

Based on this trial design, predict the completion outcome and termination type (if applicable).